ADMA BiologicsADMA -0.54%64 Return-on-Tangible-Asset is 28.31% as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, ADMA Biologics ranks better than 96.81% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ADMA Biologics's annualizedNet Income for the quarter that ended in Mar. 2026 was $181.3 Mil. ADMA Biologics's average total tangible assets for the quarter that ended in Mar. 2026 was $640.6 Mil. Therefore, ADMA Biologics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 28.31%.
The historical rank and industry rank for ADMA Biologics's Return-on-Tangible-Asset or its related term are showing as below:
ADMA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -82.34 Med: -38.67 Max: 48.82
Current: 28.44
During the past 13 years, ADMA Biologics's highest Return-on-Tangible-Asset was 48.82%. The lowest was -82.34%. And the median was -38.67%.
ADMA's Return-on-Tangible-Asset is ranked better than 96.81% of 1412
companies
in the Biotechnology industry
Industry Median: -35.475
vs ADMA: 28.44
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ADMA Biologics Return-on-Tangible-Asset Related Terms
ADMA Biologics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, ADMA Biologics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 28.31% mean?
ADMA Biologics (ADMA) has a Return-on-Tangible-Asset of 28.31% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #45 out of 1412 companies in the Biotechnology industry, placing it in the top 3.2%.
Is ADMA Biologics' Return-on-Tangible-Asset too high?
ADMA Biologics' current Return-on-Tangible-Asset is 28.31%. Based on the distribution chart, ADMA Biologics ranks #45 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Return-on-Tangible-Asset compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #45 out of 1412 companies for Return-on-Tangible-Asset. This places ADMA Biologics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Return-on-Tangible-Asset is 28.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current Return-on-Tangible-Asset is 28.31%. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Return-on-Tangible-Asset is 28.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Return-on-Tangible-Asset: 28.31%
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
